We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

25 hedge funds and large institutions have $4.44M invested in vTv Therapeutics in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

200% more capital invested

Capital invested by funds: $1.48M → $4.44M (+$2.96M)

39% more funds holding

Funds holding: 18 → 25 (+7)

0.08% more ownership

Funds ownership: 0.06% → 0.14% (+0.08%)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

Holders
25
Holders Change
+7
Holders Change %
+38.89%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
+$2.55M
2
Renaissance Technologies
Renaissance Technologies
New York
+$617K
3
Two Sigma Investments
Two Sigma Investments
New York
+$437K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$166K
5
Millennium Management
Millennium Management
New York
+$117K

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$303K
2
Bank of America
Bank of America
North Carolina
-$293K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$35K
4
ECM
ExodusPoint Capital Management
New York
-$27K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$17.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
1
Frazier Management
Washington
$2.03M +$2.55M +26,550 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$586K +$166K +1,725 +29%
Renaissance Technologies
3
Renaissance Technologies
New York
$564K +$617K +6,415 +663%
Two Sigma Investments
4
Two Sigma Investments
New York
$516K +$437K +4,549 +206%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$201K -$17.9K -186 -7%
BlackRock
6
BlackRock
New York
$120K -$1.73K -18 -1%
Millennium Management
7
Millennium Management
New York
$93K +$117K +1,221 New
Two Sigma Advisers
8
Two Sigma Advisers
New York
$72K +$91.2K +948 New
SIM
9
Spark Investment Management
New York
$46K +$58.2K +605 New
Northern Trust
10
Northern Trust
Illinois
$37K +$17.2K +179 +59%
Goldman Sachs
11
Goldman Sachs
New York
$35K +$44K +458 New
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$31K +$39.1K +407 New
WS
13
Wedbush Securities
California
$28K +$35.1K +365 New
JG
14
Jefferies Group
New York
$27K +$33.7K +350 New
Deutsche Bank
15
Deutsche Bank
Germany
$16K -$2.4K -25 -11%
Bank of America
16
Bank of America
North Carolina
$14K -$293K -3,047 -94%
PNC Financial Services Group
17
PNC Financial Services Group
Pennsylvania
$10K +$12K +125 New
Victory Capital Management
18
Victory Capital Management
Texas
$6K +$6.54K +68 New
Osaic Holdings
19
Osaic Holdings
Arizona
$4K +$4.81K +50 New
Barclays
20
Barclays
United Kingdom
$3K -$303K -3,148 -99%
UBS Group
21
UBS Group
Switzerland
$2K – – –
Morgan Stanley
22
Morgan Stanley
New York
$1K -$11.3K -117 -90%
Wells Fargo
23
Wells Fargo
California
$1K +$96 +1 +9%
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$1K +$385 +4 +50%
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
$6 – – –
1
2

VTVT Hedge Fund Activity: Q1 2020 in Review

25 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2020, worth a combined $4.44M — up 200% from $1.48M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new VTVT positions and 3 closed out — a net gain of 8 holders — while 6 added to existing stakes and 6 trimmed.

The largest buyer was Frazier Management, opening a new position worth an estimated $2.55M. The largest seller was Barclays, cutting an estimated $303K.

  • 25 institutional investors held vTv Therapeutics (VTVT) as of Q1 2020, up from 18 in Q4 2019.
  • Funds reported $4.44M of vTv Therapeutics stock for Q1 2020, up 200% quarter-over-quarter.
  • 11 funds opened new vTv Therapeutics positions in Q1 2020 and 3 closed out, a net change of +8 holders.
  • The largest vTv Therapeutics buyer in Q1 2020 was Frazier Management, an estimated $2.55M added.
  • The largest vTv Therapeutics seller in Q1 2020 was Barclays, an estimated $303K sold.

Based on aggregated 13F filings for Q1 2020.